Long-lasting improvement of refractory antisynthetase syndrome with tocilizumab: a report of two cases

Further Publications DermatologyFurther Publications ImmunologyFurther Publications Rheumatology

Long-term efficacy and safety of tocilizumab in refractory Takayasu arteritis: final results of the randomized controlled phase 3 TAKT study

Rheumatology (Oxford).

Nakaoka Y, Isobe M, Tanaka Y, Ishii T, Ooka S, Niiro H, Tamura N, Banno S, Yoshifuji H, Sakata Y, Kawakami A, Atsumi T, Furuta S, Kohsaka H, Suzuki K, Hara R, Maejima Y, Tsukamoto H, Takasaki Y, Yamashita K, Okada N, Yamakido S, Takei S, Yokota S, Nishimoto N

doi: 10.1093/rheumatology/kez630.

Melanoma and Skin Cancer

Genotypic and Phenotypic Features of BAP1 Cancer Syndrome: A Report of 8 New Families and Review of Cases in the Literature

JAMA Dermatol.

Haugh AM, Njauw CN, Bubley JA, Verzì AE, Zhang B, Kudalkar E, VandenBoom T1, Walton K, Swick BL, Kumar R, Rana HQ, Cochrane S, McCormick SR, Shea CR, Tsao H, Gerami P

doi: 10.1001/jamadermatol.

Atopic Dermatitis

Nemolizumab plus topical agents in patients with atopic dermatitis and moderate-to-severe pruritus provide improvement in pruritus and signs of atopic dermatitis for up to 68 weeks: results from two phase III, long-term studies

Br J Dermatol

Kabashima K, Matsumura T, Komazaki H, Kawashima M, Nemolizumab JP01, JP02 Study Group.

doi: 10.1111/bjd.20873

Psoriasis

Tildrakizumab efficacy, drug survival, and safety are comparable in patients with psoriasis with and without metabolic syndrome: Long-term results from two phase 3 randomized controlled studies (reSURFACE 1 and reSURFACE 2)

J Am Acad Dermatol.

Lebwohl MG, Leonardi CL, Mehta NN, Gottlieb AB, Mendelsohn AM, Parno J, Rozzo SJ, Menter MA

doi: 10.1016/j.jaad.2020.09.047.

Further Publications DermatologyFurther Publications ImmunologyFurther Publications Rheumatology

Association between two painful and poorly understood conditions: Irritable bowel and sensitive skin syndromes

Eur J Pain.

Misery L, Duboc H, Coffin B, Brenaut E, Huet F, Taieb C

doi: 10.1002/ejp.1296.

PsoriasisPsoriatic Arthritis

Apremilast, an oral phosphodiesterase 4 inhibitor, improves patient-reported outcomes in the treatment of moderate to severe psoriasis: Results of two phase III randomized, controlled trials

J Eur Acad Dermatol Venereol.

Thaçi D, Kimball A, Foley P, Poulin Y, Levi E, Chen R, Feldman SR

doi: 10.1111/jdv.13918.

Juvenile Idiopathic ArthritisRheumatoid Arthritis

Vascular imaging of patients with refractory Takayasu arteritis treated with tocilizumab: post hoc analysis of a randomized controlled trial

Rheumatology (Oxford)

Nakaoka Y, Yanagawa M, Hata A, Yamashita K, Okada N, Yamakido S, Hayashi H, Jayne D

doi: 10.1093/rheumatology/keab684

Autoimmune Disease

Effectiveness and safety of rituximab for the treatment of refractory systemic sclerosis associated calcinosis: A case series and systematic review of the literature

Autoimmun Rev.

Narváez J, Pirola JP, LLuch J, Juarez P, Nolla JM, Valenzuela A

doi: 10.1016/j.autrev.2018.10.006.

Further Publications DermatologyFurther Publications ImmunologyFurther Publications Rheumatology

Secukinumab Therapy for Netherton Syndrome

JAMA Dermatol.

Luchsinger I, Knöpfel N, Theiler M, Bonnet des Claustres M, Barbieux C, Schwieger-Briel A, Brunner C, Donghi D, Buettcher M, Meier-Schiesser B, Hovnanian A, Weibel L

doi: 10.1001/jamadermatol.2020.1019.

Related content

Long-term efficacy and safety of tocilizumab in refractory Takayasu arteritis: final results of the randomized controlled phase 3 TAKT study

Genotypic and Phenotypic Features of BAP1 Cancer Syndrome: A Report of 8 New Families and Review of Cases in the Literature

Nemolizumab plus topical agents in patients with atopic dermatitis and moderate-to-severe pruritus provide improvement in pruritus and signs of atopic dermatitis for up to 68 weeks: results from two phase III, long-term studies

Tildrakizumab efficacy, drug survival, and safety are comparable in patients with psoriasis with and without metabolic syndrome: Long-term results from two phase 3 randomized controlled studies (reSURFACE 1 and reSURFACE 2)

Association between two painful and poorly understood conditions: Irritable bowel and sensitive skin syndromes

Apremilast, an oral phosphodiesterase 4 inhibitor, improves patient-reported outcomes in the treatment of moderate to severe psoriasis: Results of two phase III randomized, controlled trials

Vascular imaging of patients with refractory Takayasu arteritis treated with tocilizumab: post hoc analysis of a randomized controlled trial

Effectiveness and safety of rituximab for the treatment of refractory systemic sclerosis associated calcinosis: A case series and systematic review of the literature

Secukinumab Therapy for Netherton Syndrome